Cell therapies are a rapidly growing market with a complex bio-manufacturing process. This necessitates the need for robust processes that can be implemented during process establishment to enable scalable and reproducible GMP manufacturing. The development of new platforms designed for specific cell therapy applications can add immense value, improving efficiency, purity, and potency, however, integration of new instruments in GMP processes requires a risk-based approach. Adopting these platforms into new workflows is critical to match the speed of therapeutic product innovations and manufacturing requirements. In this commentary, we summarize our recent publication that highlighted the critical considerations for equipment implementation into a translatable cell therapy workflow, evaluating features based on process suitability and compliance to regulatory requirements.